We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Decreased preoperative serum fibulin-3 levels in colon cancer patients.
- Authors
SIMSEK, O.; KOCAEL, A.; KEMIK, A.; VATANKULU, B.; KOCAEL, P.; HALAC, M.; ULUALP, K.; SONMEZOGLU, K.
- Abstract
OBJECTIVE: Fibulin-3 is known to play a role in tumor cell malignancy, invasion and metastasis, as well as in the clinical progression of tumors. This study aimed to assess serum fibulin-3 levels in patients with colon cancer compared with healthy controls and its relationship to demographics and tumor pathology. PATIENTS AND METHODS: A total of 80 patients (mean age, 58.99 years; 42% males) with colon cancer and 50 controls (mean age, 57.75; 55% males) were included. Serum levels of fibulin-3 were determined using a commercially available sandwich ELISA (Enzyme-Linked ImmunoSorbent Assay). RESULTS: Preoperative serum fibulin-3 levels were significantly lower in the group of patients with colon cancer (mean, 35.91 ng/mL; range, 10-73 ng/mL) compared with the control group (mean, 96.68 ng/mL; range, 57-168 ng/mL). CONCLUSIONS: It was concluded that fibulin-3 is expressed at a lower level in colon cancer, and it can serve as a marker for advanced colon cancer.
- Subjects
SERUM; FIBULINS; GLYCOPROTEIN genetics; COLON cancer patients; CANCER cells; PHYSIOLOGY; GENETICS
- Publication
European Review for Medical & Pharmacological Sciences, 2015, Vol 19, Issue 21, p4076
- ISSN
1128-3602
- Publication type
Article